ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SION vs ORMP // ALTMAN Z-SCORE & DEBT/EQUITY

Sionna Therapeutics Inc. (NASDAQ) VS. Oramed Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: SION 1 — ORMP 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SION VS. ORMP) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SION ORMP SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 0.70% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -28.30% -7.80% -20.50 ORMP /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -5.20% — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — 3.80% — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 3/9 -1.00 ORMP /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 33.5 40.6 -7.10 ORMP /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $175.0M $171.0M $4.0M SION /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SION REV ORMP REV SION GROSS % ORMP GROSS % SION FCF ORMP FCF
FY 2025 $249.1M $2.0M — 0.7% -$66.7M -$9.2M
FY 2024 $197.6M $35.8M — — -$52.8M -$8.4M
FY 2023 — $1.3M — — — -$10.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SION // BETA —
ORMP // BETA —